Biorestorative Therapies, Inc. (NASDAQ:BRTX – Get Free Report) was the target of a significant increase in short interest in the month of May. As of May 29th, there was short interest totaling 6,588,718 shares, an increase of 1,687.2% from the May 14th total of 368,665 shares. Approximately 29.9% of the shares of the company are short sold. Based on an average daily volume of 65,163,071 shares, the short-interest ratio is currently 0.1 days.
Hedge Funds Weigh In On Biorestorative Therapies
Several hedge funds and other institutional investors have recently modified their holdings of BRTX. Citadel Advisors LLC acquired a new stake in Biorestorative Therapies in the 3rd quarter valued at $152,000. DRW Securities LLC acquired a new position in Biorestorative Therapies during the fourth quarter worth $55,000. Finally, Virtu Financial LLC raised its stake in Biorestorative Therapies by 102.4% during the third quarter. Virtu Financial LLC now owns 24,351 shares of the company’s stock worth $35,000 after acquiring an additional 12,319 shares in the last quarter. Institutional investors own 69.38% of the company’s stock.
Analysts Set New Price Targets
Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Biorestorative Therapies in a research report on Wednesday, May 27th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company currently has a consensus rating of “Sell”.
Biorestorative Therapies Price Performance
Shares of Biorestorative Therapies stock traded up $0.03 during trading on Tuesday, hitting $0.39. 1,008,341 shares of the company’s stock traded hands, compared to its average volume of 30,628,912. The company has a market cap of $10.05 million, a PE ratio of -0.37 and a beta of 0.67. The firm’s fifty day moving average price is $0.27 and its 200 day moving average price is $0.62. Biorestorative Therapies has a twelve month low of $0.16 and a twelve month high of $2.05.
Biorestorative Therapies (NASDAQ:BRTX – Get Free Report) last announced its quarterly earnings results on Thursday, May 14th. The company reported ($0.19) EPS for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.01. The firm had revenue of $0.02 million during the quarter, compared to analysts’ expectations of $0.31 million. Biorestorative Therapies had a negative net margin of 3,088.27% and a negative return on equity of 508.42%. As a group, equities research analysts anticipate that Biorestorative Therapies will post -0.66 earnings per share for the current year.
Biorestorative Therapies Company Profile
Biorestorative Therapies Inc (NASDAQ: BRTX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of regenerative tissue therapy products. The company leverages a proprietary universal allogeneic cell technology platform to create high-potency cell therapy candidates designed to promote tissue repair, reduce inflammation and accelerate healing in areas damaged by disease or medical treatment.
Its lead development program targets radiation-induced oral mucositis (RIOM), a painful and dose-limiting side effect experienced by head and neck cancer patients undergoing radiotherapy.
Featured Stories
- Five stocks we like better than Biorestorative Therapies
- The Bank of Mom and Dad Is Booming—3 Stocks to Watch
- Corning Is Paving AI’s Future With Glass
- Why’s Amazon Suddenly Lagging the S&P 500, and Is It a Warning?
- Crypto Winter Is Here: 3 Stocks To Put On Ice This Summer
Receive News & Ratings for Biorestorative Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biorestorative Therapies and related companies with MarketBeat.com's FREE daily email newsletter.
